Videos

Yousef Zakharia, MD, assistant professor, University of Iowa, Holden Comprehensive Cancer Center, discusses indoximod as an active IDO inhibitor in advanced melanoma.

Denise Yardley, MD, senior investigator at the Sarah Cannon Research Institute, discusses the role of nab-paclitaxel (Abraxane) in the treatment of triple-negative breast cancer (TNBC). 

Elizabeth Swisher, MD, professor, Department of Medicine, Division of Medical Genetics, University of Washington School of Medicine, discusses a study that explored methylation as a predictor for response in ovarian cancer.

Anna Farago, MD, PhD, discusses a phase I study of olaparib (Lynparza) and temozolomide (Temodar) in patients with small cell lung cancer who had progression after 1 prior line of platinum-based chemotherapy.

Uncontrolled Polycythemia Vera

Manish A. Shah, MD, director of gastrointestinal oncology, Weill Cornell Medicine and New York-Presbyterian Hospital, discusses findings of how early-onset colorectal cancer is distinct from traditional colorectal cancer.

Jason J. Luke, MD, assistant professor of Medicine, The University of Chicago Medicine, discusses immunotherapy combinations on the horizon in melanoma.

Treatment of Advanced Ovarian Cancer, with Thomas Herzog, MD

Elizabeth A. Mittendorf, MD, PhD, associate professor, department of surgical oncology, University of Texas MD Anderson Cancer Center, discusses the promise immunotherapy has shown thus far in breast cancer, particularly triple-negative breast cancer (TNBC). 

Daniel James George, MD, professor of Medicine, professor in Surgery, Duke University School of Medicine, discusses how cabozantinib (Cabometyx) is currently being used in practice for patients with renal cell carcinoma (RCC).

Metastatic CRC Progressing on Multiple Therapies

Barbara McAneny, MD, the chief executive officer of New Mexico Cancer Center, discusses how oral targeted therapies and immunotherapies disrupted the traditional methods for financing community practices.

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the trial of MEK162 in combination with gemcitabine and cisplatin in patients with untreated advanced biliary cancer.

Recurrent Colon Cancer with Liver Metastases